MONOPAR THERAPEUTICS (MNPR)

Today's Latest Price: $4.84 USD

0.00 (0.00%)

Updated Dec 4 3:58pm

Add MNPR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Monopar Therapeutics (MNPR) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Monopar Therapeutics.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
3 $42 $11 $31 $4.845 539.83%

MNPR Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 2 0 0 0 0 2

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MNPR as an investment opportunity.

  • MNPR has a less percent of analysts bearish on the stock than nearly 100% of all US stocks.
  • MNPR has a lower variance in analysts' estimates than 4.12% of stocks in the micro market cap category.
  • Monopar Therapeutics's upside potential (average analyst target price relative to current price) is greater than 95.81% of all US stocks.
  • The average analyst price target of MNPR is greater than 90.02% of stocks in the micro market cap category.
  • Monopar Therapeutics's percentage of analysts bullish on the stock is higher than 82.08% of all US stocks.
  • The number of analysts covering the stock of MNPR is greater than 21.48% of Pharmaceutical Products stocks.
  • MNPR has a lower change in bullishness amongst analysts than nearly 100% of all US stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Monopar Therapeutics are NOVN, MBRX and ORMP.

Make investment decisions regarding MNPR using the data that counts. Try POWR Ratings for free.



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4544 seconds.